ProfileGDS5678 / 1433627_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 82% 83% 81% 85% 83% 81% 86% 84% 85% 83% 81% 84% 85% 83% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.885282
GSM967853U87-EV human glioblastoma xenograft - Control 26.1063583
GSM967854U87-EV human glioblastoma xenograft - Control 35.7533781
GSM967855U87-EV human glioblastoma xenograft - Control 46.52185
GSM967856U87-EV human glioblastoma xenograft - Control 56.1059383
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.5917881
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.2808986
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.1899784
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.3529685
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.0554483
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.7550781
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.2590884
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.3180285
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.1001383